Results 241 to 250 of about 41,565 (267)
Some of the next articles are maybe not open access.
Laquinimod in the treatment of relapsing remitting multiple sclerosis
Expert Opinion on Drug Metabolism & Toxicology, 2016Laquinimod is a new once-daily oral administrable agent, which is under investigation in a phase 3 clinical trial for relapsing remitting multiple sclerosis (RRMS) and in a phase 2 clinical trial for primary progressive MS (PPMS).The pharmacokinetic, pharmacodynamic and the safety profiles of laquinimod are covered in this review.
Undine Hainke +2 more
openaire +2 more sources
FADD Is Upregulated in Relapsing Remitting Multiple Sclerosis
Neuroimmunomodulation, 2014<b><i>Objective:</i></b> To elucidate the role of tumor necrosis factor (TNF) receptor signal transduction in multiple sclerosis (MS). <b><i>Methods:</i></b> We performed a cross-sectional analysis of the gene expression of TNF receptor-associated death domain protein (TRADD) and Fas-associated death ...
Reinhard, Reuss +5 more
openaire +2 more sources
Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
Reviews on Recent Clinical Trials, 2010Disease modifying therapy (DMT) first became available for relapsing-remitting multiple sclerosis (RRMS) fifteen years ago with the development of the moderately effective injectable agents interferon (IFN)-beta and glatiramer acetate (GA). The subsequent licensure of mitoxantrone (MX) and natalizumab (NZ) has allowed for better control of refractory ...
James J, Marriott, Paul W, O'Connor
openaire +2 more sources
Alemtuzumab for the Treatment of Relapsing–Remitting Multiple Sclerosis
Immunotherapy, 2014Alemtuzumab, a humanized monoclonal antibody that targets CD52, was recently approved in the EU and Canada for the treatment of patients with active relapsing-remitting multiple sclerosis. Alemtuzumab induces rapid depletion of circulating B- and T-lymphocytes followed by repopulation that leads to a distinctive lymphocyte profile, including an ...
Carrie M, Hersh, Jeffrey A, Cohen
openaire +2 more sources
Teriflunomide for the treatment of relapsing–remitting multiple sclerosis
Expert Review of Clinical Immunology, 2014Teriflunomide, a once-daily, oral disease-modifying therapy, is a valuable new treatment option for the management of patients with relapsing-remitting multiple sclerosis. This article reviews key efficacy and safety data arising from pivotal teriflunomide studies that demonstrate the utility in treating both treatment-naïve patients and those ...
openaire +2 more sources
Teriflunomide: A Review in Relapsing–Remitting Multiple Sclerosis
Drugs, 2019Teriflunomide (Aubagio®) is a disease-modifying immunomodulatory drug with anti-inflammatory properties that selectively and reversibly inhibits the mitochondrial enzyme dihydro-orotate dehydrogenase, with consequent inhibition of de novo pyrimidine synthesis and reduced lymphocyte proliferation.
openaire +2 more sources
Alemtuzumab for relapsing-remitting multiple sclerosis
The Lancet Neurology, 2014Richard A, Diaz +4 more
openaire +2 more sources